For the quarter ending 2025-09-30, ORMP had $36,382K increase in cash & cash equivalents over the period. -$1,625K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 48,389 | 5,618 |
| Depreciation | 31 | 60 |
| Exchange differences and interest on deposits | -823 | 73 |
| Changes in fair value of investments | 61,163 | 11,429 |
| Stock-based compensation | 719 | 2,989 |
| Gain on amounts funded in respect of employee rights upon retirement | 2 | 6 |
| Prepaid expenses and other current assets | 553 | -816 |
| Accounts payable, accrued expenses and related parties | 2,673 | -3,280 |
| Net changes in operating lease | 13 | 72 |
| Deferred revenues | 0 | -2,000 |
| Deferred income | 245 | - |
| Liability for employee rights upon retirement | 2 | 6 |
| Deferred tax liabilities | -7,688 | -233 |
| Change in accrued interest on short-term borrowings | - | 0 |
| Other liabilities | 0 | -60 |
| Total net cash used in operating activities | -1,625 | -7,054 |
| Purchase of marketable securities | 1,500 | - |
| Investment at fair value | -746 | -63,571 |
| Proceeds from redemption of short-term deposits | 18,000 | 32,450 |
| Proceeds from investments | - | 4,599 |
| Proceeds from long-term deposits | - | 0 |
| Advance payments for real estate | - | 1,949 |
| Proceeds from loan to an equity method investee | 2,809 | 3,442 |
| Loan to investment in equity method | 0 | 7,000 |
| Real estate investment | 2,128 | - |
| Equity method investee | 0 | 250 |
| Proceeds from long-term investments and marketable securities | 24,579 | 1,049 |
| Purchase of short-term deposits | - | 0 |
| Purchase of property and equipment | 0 | 7 |
| Total net cash provided by investing activities | 38,364 | -31,237 |
| Loans repaid | - | 0 |
| Repurchase and retirement of common stock | 361 | 371 |
| Total net cash used in financing activities | -361 | -371 |
| Effect of exchange rate changes on cash and cash equivalents | 4 | 39 |
| Increase (decrease) in cash and cash equivalents | 36,382 | -38,623 |
| Cash and cash equivalents at beginning of period | 54,420 | - |
| Cash and cash equivalents at end of period | 52,179 | - |
ORAMED PHARMACEUTICALS INC. (ORMP)
ORAMED PHARMACEUTICALS INC. (ORMP)